Citi analyst Liav Abraham reiterated a Buy rating and $24 price target on Teva Pharma (NYSE: TEVA) saying they anticipate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE